Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110241 | 0.87 | MAPK1 (0.56) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL19668480 | 0.87 | MAPK1 (0.69) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL20110245 | 0.85 | MAPK1 (0.58) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL22060702 | 0.85 | MAPK1 (0.58) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL20110231 | 0.85 | MAPK1 (0.60) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL22060155 | 0.85 | MAPK1 (0.55) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL22060701 | 0.84 | MAPK1 (0.54) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL20110191 | 0.83 | MAPK1 (0.79) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL20110192 | 0.83 | MAPK1 (0.79) | MAPK1CDKN1AKDM4EALDH1A1LMNA | |
| SCHEMBL22060333 | 0.83 | MAPK1 (0.55) | MAPK1CDKN1AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | TP53, RB1, CDK1 | MAPK1 723/4885CDKN1A 7/4885KDM4E 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.